noodls browser compatibility check

The security settings of your browser are blocking the execution of scripts.

To use noodls, javascript support must be enabled. Please change your browser's security settings to enable javascript.

If you have changed your browser's security settings, you can click here.

related announcements

News

Willkie Farr & Gallagher LLP

Willkie Adds Restructuring Partner Jeffrey Michalik In Chicago
A.T. Still University

2025 Innovation in Teaching for Learning Awards announced
The Ensign Group Inc.

Notice of Proposed Sale of Securities (Form 144)

Healthcare

Coya Therapeutics Inc.

01/20/2026 | Press release | Distributed by Public on 01/20/2026 07:20

Material Event (Form 8-K)

Item 8.01

Other Events.

On January 20, 2026, Coya Therapeutics, Inc. (the "Company") issued a letter to its stockholders wherein it announced its cash balance as of December 31, 2025 was $46.8 million (unaudited) with projected cash runway into the second half of 2027, and that the Company expects a topline data readout from its current ALSTARS Phase 2 trial in the first quarter of 2027.

Coya Therapeutics Inc. published this content on January 20, 2026, and is solely responsible for the information contained herein. Distributed via EDGAR on January 20, 2026 at 13:21 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]